Tsuyoshi Shirakawa

10PUBLICATIONS
3CO-AUTHORS
Comparative and cross-cultural educationCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersOncology and carcinogenesis not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|May 18, 2026
Research Survey on Recognition of Medical Oncology among Medical Students and Junior Residents in Japan.

|Apr 29, 2026
Predictors of prolonged progression-free survival in patients with unresectable or recurrent pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid (NAPOLEON-2 study).

|Nov 21, 2025
Impact of prior chemotherapy on nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer: a retrospective analysis of data from the multicenter NAPOLEON-2 study.

Tomomi Koike, Yasunori Kawaguchi, Mototsugu Shimokawa

|Aug 01, 2025
Chemotherapy-induced neutropenia predicts short-term outcome of patients with pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil, and folinic acid.

Tomonori Araki, Tsuyoshi Shirakawa, Mototsugu Shimokawa

|Feb 24, 2025
Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from the NAPOLEON-2 study (NN-2302).

Tomonori Araki, Kohei Hayashi, Mototsugu Shimokawa

|Jan 27, 2025
Relationship between neutropenia caused by nanoliposomal irinotecan/fluorouracil/leucovorin and treatment outcomes in the NAPOLEON-2 study (NN-2301).

Tomonori Araki, Yuki Sonoda, Mototsugu Shimokawa

Pageof 2

Frequent Collaborators

2 joint publications

Tomonori Araki

1 joint publications

Tomomi Koike

1 joint publications

Yasunori Kawaguchi